Ionis Pharmaceuticals IONS Available For Sale Securities Debt Maturities Within Two Years Percentage
Available For Sale Securities Debt Maturities Within Two Years Percentage at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept ions:AvailableForSaleSecuritiesDebtMaturitiesWithinTwoYearsPercentage.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's available for sale securities debt maturities within two years percentage.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's available for sale securities debt maturities within two years percentage?
- Ionis Pharmaceuticals (IONS) reported available for sale securities debt maturities within two years percentage of 94% in Q1 2026.
- How has Ionis Pharmaceuticals's available for sale securities debt maturities within two years percentage changed year-over-year?
- Ionis Pharmaceuticals's available for sale securities debt maturities within two years percentage decreased by 0.0% year-over-year, from 94% to 94%.
- What does available for sale securities debt maturities within two years percentage mean?
- The portion of debt securities in the investment portfolio maturing within the next two years.
- How do you interpret available for sale securities debt maturities within two years percentage?
- Higher percentages indicate better near-term liquidity and lower interest rate risk, while lower percentages suggest a longer-duration investment strategy.
- How does available for sale securities debt maturities within two years percentage compare across companies?
- Peer companies in the pharmaceutical sector often align maturity profiles with anticipated clinical trial funding requirements.